OBJECTIVES: Systemic thrombolysis improves outcomes in patients with pulmonary
embolism (PE) but is associated with the risk of hemorrhage. The data on efficacy and safety …

Objectives: Recent evidence suggests that half-dose thrombolysis for pulmonary embolism
may provide similar efficacy with reduced bleeding risk compared with full-dose therapy, but …

Recent guidelines recommend bolus-dose alteplase for treating massive pulmonary
embolism (PE). However, the safest and most effective treatment is as yet unknown. In the …

Study objective To test the hypothesis that a reduced dose of bolus recombinant human
tissue-type plasminogen activator (rt-PA)(0.6 mg/kg/15 min, maximum of 50 mg) would result …

Objective: To review and evaluate the evidence regarding the use of low-dose regimens of
alteplase (tPA) for the treatment of pulmonary embolism (PE). Data Sources: A PubMed …

The Bolus Alteplase Pulmonary Embolism (BAPE) Group and a consortium of French
investigators utilized essentially the same investigational protocol to test reduced dose bolus …

Guidelines-recommend thrombolytic therapy for pulmonary embolism in patients with severe
hemodynamic compromise and low risk of bleeding. Thrombolytics in submassive …

Intermediate–high-risk pulmonary embolism (PE) is characterized by right ventricular (RV)
dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic …

Acute pulmonary embolism accounts for 50 000 to 100 000 deaths each year in the United
States. Because of the wide spectrum of clinical manifestations, ranging from massive …

Background: We report a case series of two patients in the intensive care unit with massive
pulmonary embolism and obstructive shock who had resolution of shock after repeated …